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ABSTRACT
Hypophosphatasia (HPP) is the heritable metabolic disease characterized by impaired skeletal mineralization due to low activity of the
tissue-nonspeciﬁc isoenzymeof alkaline phosphatase. AlthoughHPP during growth oftenmanifestswith distinctive radiographic skeletal
features, no validated method was available to quantify them, including changes over time. We created the Radiographic Global
ImpressionofChange (RGI-C) scale toassess changes in the skeletal burdenofpediatricHPP. Site-speciﬁcpairsof radiographsofnewborns,
infants, and children with HPP from three clinical studies of asfotase alfa, an enzyme replacement therapy for HPP, were obtained at
baseline and during treatment. Each pair was scored by three pediatric radiologists (“raters”), with nine raters across the three studies.
Intrarater and interrater agreement was determined by weighted Kappa coefﬁcients. Interrater reliability was assessed using intraclass
correlation coefﬁcients (ICCs) and by two-way random effects analysis of variance (ANOVA) and a mixed-model repeated measures
ANOVA. Pearson correlation coefﬁcients evaluated relationships of the RGI-C to the Rickets Severity Scale (RSS), Pediatric Outcomes Data
Collection Instrument Global Function Parent Normative Score, Childhood Health Assessment Questionnaire Disability Index, 6-Minute
Walk Test percent predicted, and Z-score for height in patients aged 6 to 12 years at baseline. Eighty-nine percent (8/9) of raters showed
substantial or almost perfect intrarater agreement of sequential RGI-C scores (weighted Kappa coefﬁcients, 0.72 to 0.93) andmoderate or
substantial interrater agreement (weighted Kappa coefﬁcients, 0.53 to 0.71) in patients aged 0 to 12 years at baseline. Moderate-to-good
interrater reliabilitywasobserved (ICC, 0.57 to 0.65). RGI-C scoreswere signiﬁcantly (p 0.0065) correlatedwith theRSSandwithmeasures
of global function, disability, endurance, and growth in the patients aged 6 to 12 years at baseline. Thus, the RGI-C is valid and reliable for
detecting clinically important changes in skeletal manifestations of severe HPP in newborns, infants, and children, including during
asfotase alfa treatment. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
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Introduction
Hypophosphatasia (HPP) is the rare inborn-error-of-metabolismcharacterized enzymatically by low activity of the tissue-
nonspeciﬁc isoenzyme of alkaline phosphatase (TNSALP) and
caused by loss-of-function mutation(s) in ALPL (TNSALP), the
gene that encodes this cell-surface phosphohydrolase.(1–3) To
date, more than 340 such mutations, primarily missense defects,
have been identiﬁed in patients with HPP.(4) The inheritance
pattern may be autosomal recessive or autosomal dominant.(2,5)
Consequently, HPP is characterized by remarkably broad-ranging
severity and can be lethal in utero or not manifest until late adult
life.(5) In HPP, extracellular accumulation of inorganic pyrophos-
phate, a potent inhibitor of mineralization, often leads to rickets
or osteomalacia.(6) In affected newborns, infants, and children,
HPP can cause limb deformity, muscle weakness, musculoskeletal
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pain, fractures, poor growth, and premature loss of deciduous
teeth.(3,6) When HPP presents during growth, radiography can
uncover skeletal features that are pathognomonic.(1,3,7)
In 2000, a Rickets Severity Scale (RSS) was developed to assess
radiographic features in the wrists and knees of patients with
nutritional rickets.(8) Because assessing radiographic features is
also important for patients with skeletal manifestations of HPP,
a scale that encompasses the characteristic changes of HPP
seemed necessary to best evaluate therapeutic responses.(7)
Herein, we describe and validate the Radiographic Global
Impression of Change (RGI-C) scale as a tool for scoring changes
over time in key radiographic features of HPP in pediatric
patients. Our evaluation of the RGI-C measured agreement and
reliability of scores given by multiple raters to select radio-
graphs, and then we determined the correlation of the scores
to other outcome measures using data from three recently
completed clinical studies of asfotase alfa treatment (Strensiq®;
Alexion Pharmaceuticals, Inc., New Haven, CT, USA), an enzyme
replacement therapy approvedmultinationally in 2015, typically
for the treatment of pediatric-onset HPP.(9–11)
Materials and Methods
Development of the RGI-C scale
To assess the skeletal burden of pediatric HPP, an author
(WHM, an expert concerning the radiologic evaluation of HPP)
identiﬁed key radiographic features of pediatric HPP in patients
5 and5 years of age (Table 1; Fig. 1A and B). The initial version
of the RGI-C scale evaluated the changes between time points
in irregularity of the provisional zone of calciﬁcation; physeal
widening; metaphyseal ﬂaring, fraying, radiolucencies, and
patchy osteosclerosis; altered ratio of mid-diaphyseal cortex-
to-bone thickness; gracile bones; absence of some or all bones;
and recent fractures. Then a seven-point RGI-C scale (Fig. 2) was
developed by a consensus panel of expert pediatric radiologists
chosen by WHM.
RGI-C training
The consensus panel of expert pediatric radiologists (“raters”)
was trained concerning the identiﬁcation of the abnormalities
of pediatric HPP and the RGI-C by author WHM. Imaging
instrumentation representatives (Biomedical Systems, St. Louis,
MO, USA) provided additional instruction regarding applicable
regulations and guidelines, computer requirements, and proper
data reporting. All study personnel involved in data collection
and management were given an Imaging Services Review
Charter that described the process and procedures for
radiographic collection, tracking, data quality assurance,
anonymizing data, qualiﬁcation/training, and independent
review procedures.
Data collection for validation
Per protocol, baseline and subsequent radiographs were
obtained from patients with HPP aged 12 years at study entry
for evaluation of asfotase alfa therapy. At baseline, patients were
3 years old in study ENB-002-08 with extension ENB-003-08
(NCT00744042, NCT01205152), 5 years old in study ENB-010-
10 (NCT01176266), and 6 to 12 years old in study ENB-006-09
with extension ENB-008-10 (NCT00952484, NCT01203826).
Radiographic assessments for this analysis were performed
from March 2013 to December 2014 for Study ENB-002-08/ENB-
003-08, from March 2013 to August 2014 for Study ENB-010-10,
and from November 2010 to December 2014 for Study ENB-006-
09/ENB-008-10. The RGI-C scores compared radiographic
ﬁndings at baseline with those at treatment weeks 4, 12, 24,
36, 48, 60, 72, 96, 120, 144, 168, 192, 216, and 240 for both the
ENB-002-08/ENB-003-08 and ENB-010-10 studies and weeks 6,
12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, and 216 for the ENB-
006-09/ENB-008-10 study.
Paired radiographs of the chests of patients aged <5 years
and hands/wrists and knees of all patients at baseline and
during treatment were scored independently by the raters
using the RGI-C. Of the six individual raters who were
recruited, the same three raters assessed all radiographs
from studies ENB-002-08/ENB-003-08 and ENB-010-10,
whereas the three other raters assessed radiographs from
study ENB-006-09/ENB-008-10. The radiograph pairs from ENB-
002-08/ENB-003-08 and ENB-010-10 were read sequentially by
the same raters but were not interspersed (ie, raters read all
radiographs from ENB-002-08/ENB-003-08 ﬁrst and then all
radiographs from ENB-010-10). The raters were blinded to
Table 1. Radiographic features of HPP evaluated by RGI-C
Patients 5 years of age
(ENB-002-08/ENB-003-08 and ENB-010-10)
Patients 5 years of age
(ENB-006-09/ENB-008-10)
Metadiaphyseal patchy focal sclerosis Metadiaphyseal sclerosis
Apparent physeal widening Apparent physeal widening
Irregularity of the provisional zone of calcification Irregularity of the provisional zone of calcification
Metaphyseal radiolucencies
(“tongues” or rounded areas)
“Popcorn calcifications” of metadiaphyses (rounded lucencies and
patchy sclerosis)
Metaphyseal flaring Transverse subphyseal band of lucency
Metaphyseal fraying Osteopenia of short tubular bones (evaluated for hands/wrists)
Thin, gracile bones Osteopenia (evaluated for knees)
Apparent absence of some
or all bones
Metaphyseal radiolucencies (tongues or rounded areas, evaluated for
hands/wrists)
Thin ribs Tongues of radiolucency (evaluated for knees)
Chest deformity Metaphyseal fraying (evaluated for hands/wrists)
Evidence of recent fractures Physeal corner defects (evaluated for knees)
Demineralization of the distal metaphyses (evaluated for hands/wrists)
HPP¼hypophosphatasia; RGI-C¼ Radiographic Global Impression of Change.
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patient identiﬁers, intervention status, and duration between
radiographs.
Intrarater agreement
To determine individual (“intrarater”) agreement between
repeated assessments, approximately 30 pairs of radiographs
were reread in a different session by each rater for each of the
three treatment studies (approximately 90 pairs). The percen-
tages of radiograph sets (initial and second assessment) that
were given identical scores (exact agreement), and scores within
one point for each rater, were calculated. Then, a weighted
Kappa coefﬁcient (with quadratic weights following Fleiss and
Cohen(13)) was used to estimate intrarater agreement. For the
validation, the level of agreement to the weighted Kappa
coefﬁcient was categorized as “almost perfect” (1.00 to 0.80),
Fig. 1. Skeletal features of HPP evaluated by the RGI-C for infants (A) and children (B). RGI-C¼ Radiographic Global Impression of Change;
HPP¼hypophosphatasia. (Republishedwithpermission fromWhyteMP, et al. N Engl JMed. 2012;366:904–13(9) andWhyteMP, et al. JCI Insight. 2016;e85971(12)).
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“substantial” (0.79 to 0.60), “moderate” (0.59 to 0.40), “fair” (0.39
to 0.20), “slight” (0.19 to 0.00), or “poor”(<0.00).(14)
Interrater agreement
To assess group (“interrater”) agreement for each of the three
studies, percentages of radiograph pairs assigned either
identical RGI-C scores between two raters (exact agreement),
or scores within one point between two raters, were identiﬁed.
Then, a weighted Kappa coefﬁcient (with quadratic weights
following Fleiss and Cohen(13)) was used to estimate
interrater agreement.(14) The level of agreement assigned to
the weighted Kappa coefﬁcients was as described in the
previous section for the intrarater agreement. Interrater
reliability was assessed by calculating intraclass correlation
coefﬁcients (ICCs) using a two-way random effects analysis of
variance (ANOVA), pooling the similar patient populations of
studies ENB-002-08/ENB-003-08 and ENB-010-10, and perform-
ing a separate analysis for the older patients in study ENB-
006-09/ENB-008-10. The variables for the two-way ANOVA
were subject-visit, rater, and interaction between subject-visit
and rater. The interrater reliability for the ICC was deﬁned as
“excellent” (0.75), “good” (0.6 to 7.4), “fair” (0.4 to 0.59), or
“poor” (<0.4).(15)
Interrater variability
To assess (i) the sources of variability in rater scores, (ii) whether
the level of agreement between them was greater than would
be expected by chance, and (iii) differences between raters, we
performed a mixed-model repeated measures (MMRM) AN-
OVA.(16) The dependent variable for the MMRMwas RGI-C score,
and the independent variables were subject, visit, rater, and
interaction between visit and rater.
Correlations of RGI-C to changes in other outcomemeasures
Toassess for validationof theRGI-C, Pearsoncorrelation coefﬁcients
were calculated to compare the RGI-C with ﬁve other outcome
measures: RSS,(8) Pediatric Outcomes Data Collection Instrument
(PODCI) Global Function Parent Normative Score,(17) Childhood
Health Assessment Questionnaire (CHAQ) Disability Index,(17)
6-Minute Walk Test (6MWT) (% predicted values based on age-,
sex-, and height-matched healthy peers),(18) and height Z-score.(19)
Results
Expert radiologists
Six expert pediatric radiologists participated as raters across the
three studies and evaluated a total of 363 radiographs. Three
of the six raters evaluated radiographs from the two studies
that focused on severely affected infants and young children
(ENB-002-08/ENB-003-08 and ENB-010-10; Table 2).
Intrarater agreement
Among the nine groups of ratings (three raters for each of the
three studies), intrarater agreement was considered almost
perfect for four raters (44%), substantial for four raters (44%)
Fig. 2. RGI-C scale (7-point scale) for pediatric HPP. RGI-C¼ Radiographic Global Impression of Change; HPP¼hypophosphatasia.
Table 2. Intrarater Agreement of Sequential RGI-C Scores
Study/rater
Radiograph sets
assessed (n)a
Identical RGI-C
score (%)
RGI-C score within
1 point (%)
Weighted Kappa coefficient
(95% confidence limits, LL–UL)b
ENB-002-08/ENB-003-08: Newborns, infants, and children 3 years of age(9)
Rater 1 30 77 97 0.90 (0.79–1.00)
Rater 2 30 80 97 0.77 (0.60–0.95)
Rater 3 30 87 97 0.93 (0.84–1.00)
ENB-010-10: Patients 5 years of age
Rater 1 30 53 93 0.58 (0.41–0.75)
Rater 2 27 74 93 0.76 (0.50–1.00)
Rater 3 30 70 90 0.86 (0.73–0.99)
ENB-006-09/ENB-008-10: Children 5 to 12 years of age(12)
Rater 4 27 48 96 0.78 (0.64–0.91)
Rater 5 27 56 85 0.72 (0.57–0.87)
Rater 6 24 63 96 0.83 (0.70–0.96)
RGI-C¼ Radiographic Global Impression of Change; LL¼ lower limit; UL¼ upper limit.
aIncludes number of radiograph sets where rater was able to assign a RGI-C score to both sets.
bLevel of agreement to the weighted Kappa coefﬁcient was categorized as: “almost perfect” (1.00–0.80), “substantial” (0.79–0.60), “moderate” (0.59–
0.40), “fair” (0.39–0.20), “slight” (0.19–0.00), or “poor” (<0.00).
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(weighted Kappa coefﬁcients: 0.83 to 0.93 and 0.72 to 0.78,
respectively), and moderate for one rater (11%) (weighted
Kappa coefﬁcient: 0.58). Raters assigned identical RGI-C scores
48% to 87%of the time, and assigned scores within one point (of
a total of seven points) on their ﬁrst and second assessments
85% to 97% of the time (Table 2).
Interrater agreement
Among the nine groups of ratings, direct comparisons between
raters’ RGI-C scores across the three treatment studies showed
that interrater agreement was substantial for ﬁve raters (56%),
moderate for three raters (33%), and fair for one rater (11%)
(weighted Kappa coefﬁcients: 0.60 to 0.71, 0.53 to 0.59, and 0.38,
respectively). RGI-C scores were identical 53% to 68% of the
time, and were within one point 87% to 98% of the time
(Table 3).
In an additional assessment for interrater variability, the ICC
was 0.65 after pooling the similar patient populations of studies
ENB-002-08/ENB-003-08 and ENB-010-10 that involved infants
and young children, and 0.57 for study ENB-006-09/ENB-008-10
that involved older children (Table 4A), indicating “good-to-fair”
reproducibility. To evaluate the sources of variability in RGI-C
scores, the ANOVAs (calculated using the MMRM for visit, rater,
and inﬂuences of both the speciﬁc visit and rater) showed
statistically signiﬁcant differences for the visit (p< 0.0001 in
each study), but not for rater or interaction between visit and
rater variables (Table 4B).
Correlations to changes in other outcome measures
There was moderate to strong correlation of the RGI-C to
change from baseline in the RSS scores (r¼ –0.664;
p< 0.0001; Fig. 3A). The scores from the RGI-C were
signiﬁcantly (p 0.0065) and directionally consistent with
changes from baseline in the four other outcome measures
tested: PODCI Global Function Parent Normative Score
(r¼ 0.595; Fig. 3B), CHAQ Disability Index (r¼ –0.589; Fig.
3C), 6MWT % predicted (r¼ 0.284; Fig. 3D), and Z-score for
height (r¼ 0.261; Fig. 3E).
Table 3. Interrater Agreement of Sequential RGI-C Scores
Study/rater pair
Radiograph sets
assessed (n)a
Identical RGI-C
score (%)
RGI-C score within
1 point (%)
Weighted Kappa coefficient
(95% confidence limits, LLUL)b
ENB-002-08/ENB-003-08: Newborns, infants, and children 3 years of age(9)
Rater 1 versus 2 196 54 90 0.38 (0.24–0.53)
Rater 1 versus 3 200 68 92 0.60 (0.45–0.74)
Rater 2 versus 3 196 66 98 0.71 (0.64–0.79)
ENB-010-10: Patients 5 years of age
Rater 1 versus 2 160 61 88 0.53 (0.34–0.71)
Rater 1 versus 3 166 63 89 0.69 (0.60–0.79)
Rater 2 versus 3 159 58 87 0.54 (0.38–0.70)
ENB-006-09/ENB-008-10: Children 5–12 years of age(12)
Rater 4 versus 5 287 56 97 0.64 (0.57–0.70)
Rater 4 versus 6 287 54 96 0.67 (0.61–0.73)
Rater 5 versus 6 287 53 95 0.59 (0.53–0.66)
RGI-C¼ Radiographic Global Impression of Change; LL¼ lower limit; UL¼ upper limit.
aIncludes number of radiograph sets where raters were able to assign a RGI-C score to both sets.
bLevel of agreement to the weighted Kappa coefﬁcient was categorized as: “almost perfect” (1.00–0.80), “substantial” (0.79–0.60), “moderate” (0.59–
0.40), “fair” (0.39–0.20), “slight” (0.19–0.00), or “poor” (<0.00).
Table 4. Interrater Reliability of RGI-C Scores
(A) Intraclass correlation coefficients
Study Radiographs analyzed (n) ICCa p-valueb
ENB-002-08/ENB-003-08 and ENB-010-10 227 0.65 <0.0001
ENB-006-09/ENB-008-10 136 0.57 <0.0001
(B) Mixed-model repeated measures analysis of variance
p-valueb
Study Visit Rater Interaction
ENB-002-08/ENB-003-08 and ENB-010-10 <0.0001 0.42 0.17
ENB-006-09/ENB-008-10 <0.0001 0.36 0.88
RGI-C¼ Radiographic Global Impression of Change; ICC¼ intraclass correlation coefﬁcient.
aLevel of agreement for the ICC was deﬁned as “excellent” (0.75), “good” (0.6–0.74), “fair” (0.4–0.59), and “poor” (<0.4).
872 WHYTE ET AL. Journal of Bone and Mineral Research
Discussion
Based on speciﬁed radiographs of affected newborns, infants,
and children, we developed the RGI-C scale to address the
unmet need to quantify changes in key skeletal manifestations
of pediatric HPP. The RGI-C scale was one of the primary
outcome measures in our natural history and treatment
studies leading to multinational approval in 2015 of asfotase
alfa, typically for pediatric-onset HPP.(9,10,12) The current study
validates the RGI-C using data from the three pediatric clinical
studies of asfotase alfa treatment,(9,12) in which the RGI-C scale
was scored by pediatric radiologists (blinded to patient
identiﬁers, intervention status, and duration between radio-
graphs). Good to moderate intrarater and interrater agreement
was achieved. The tests then chosen for validation were the
RSS (used to radiographically assess nutritional rickets),
validated instruments of pediatric global function (PODCI),
disability (CHAQ), and endurance (6MWT), as well as Z-scores
of patient height. All ﬁve of these assessments showed
signiﬁcant correlations with the RGI-C scores and thus
concurrent validity.
For the three pediatric clinical studies of asfotase alfa, the RGI-
C scale was crucial for evaluation of severely affected newborns,
infants, and children with HPP.(9,12) It enabled precise assess-
ment of the skeletal complications noninvasively. In fact,
other measures to study the skeleton (eg, dual-energy X-ray
absorptiometry, computed tomography, bone biopsy) were not
feasible in the smallest and initially extremely sick patients.(9)
Therefore, the RGI-C became the primary efﬁcacy outcome
measure.(9,12) In addition, the RGI-C proved feasible and
important for retrospective evaluation of skeletal status in a
natural history study of patients with HPP aged 5 to 12 years
(NCT02104219). The RGI-C will therefore be useful for future
clinical investigations of similarly affected pediatric HPP
patients. Furthermore, the RGI-C could be modiﬁed to assess
the severity of skeletal manifestations of HPP at a single time
point, although this was not evaluated in our current analysis.
However, the RGI-C scale is limited in HPP because it assesses
pediatric patients (ie, those with open growth plates) but not
adults. Furthermore, the raters in this study were all academic
pediatric radiologists with expertise concerning skeletal disease
in infants and children. Therefore, the important intrarater and
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interrater agreement observed herein for pediatric HPP may not
be generalizable. The RGI-C could be useful for perplexing single
cases requiring quantitative data or perhaps be offered by a
central facility with a particular interest in pediatric HPP.
Our study validates the RGI-C scale for assessment of
changes in the skeletal manifestations of severely affected
newborns, infants, and children with HPP. In fact, the RGI-C was
subsequently tailored to investigate the effects of the fully
human anti–ﬁbroblast growth factor 23 monoclonal antibody
burosumab to treat children with X-linked hypophosphate-
mia.(20) Thus, the RGI-C scale could be similarly useful for other
forms of rickets.
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